Humana Inc. (NYSE:HUM) Shares Sold by BloombergSen Inc.

Key Points

• BloombergSen Inc. reduced its stake in Humana Inc. by 1.7% during the first quarter, owning a total of 119,708 shares valued at approximately $31.7 million.
• Humana's stock price increased by $9.01 to $238.22, with a market cap of $28.75 billion and a P/E ratio of 16.85.
• Wall Street Analysts have mixed ratings for Humana, with the consensus price target set at $282.43, indicating an average rating of "Hold" among analysts.

BloombergSen Inc. reduced its stake in Humana Inc. (NYSE:HUM - Free Report) by 1.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,708 shares of the insurance provider's stock after selling 2,098 shares during the quarter. Humana comprises approximately 2.0% of BloombergSen Inc.'s portfolio, making the stock its 14th biggest holding. BloombergSen Inc. owned approximately 0.10% of Humana worth $31,675,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of HUM. denkapparat Operations GmbH purchased a new stake in Humana during the 4th quarter valued at about $323,000. Allstate Corp purchased a new stake in shares of Humana during the fourth quarter valued at approximately $905,000. Deutsche Bank AG grew its holdings in shares of Humana by 18.2% in the fourth quarter. Deutsche Bank AG now owns 631,371 shares of the insurance provider's stock worth $160,185,000 after purchasing an additional 97,071 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in shares of Humana in the first quarter worth approximately $1,309,000. Finally, Fred Alger Management LLC bought a new position in shares of Humana in the fourth quarter worth approximately $451,000. 92.38% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HUM. Raymond James Financial upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 target price on the stock in a report on Thursday, May 1st. Truist Financial lowered their price target on shares of Humana from $280.00 to $260.00 and set a "hold" rating for the company in a research report on Wednesday, July 16th. Guggenheim assumed coverage on Humana in a research report on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price target for the company. Mizuho lifted their target price on Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a report on Wednesday, April 9th. Finally, Bank of America lowered their price objective on shares of Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a research report on Tuesday, June 17th. Sixteen analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $282.43.

Humana Trading Up 3.9%

Shares of NYSE HUM traded up $9.01 during trading on Friday, reaching $238.22. The stock had a trading volume of 1,569,145 shares, compared to its average volume of 1,505,668. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.91 and a current ratio of 1.91. The company has a market cap of $28.75 billion, a P/E ratio of 16.85, a PEG ratio of 1.57 and a beta of 0.44. The business's 50-day moving average price is $234.56 and its 200-day moving average price is $256.27. Humana Inc. has a fifty-two week low of $206.87 and a fifty-two week high of $406.09.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. Humana had a net margin of 1.42% and a return on equity of 14.47%. The firm's quarterly revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $7.23 earnings per share. On average, equities research analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.